Ozempic for Adults 65 and Older: School, Activity, and Daily Life Considerations

What the label says about semaglutide in adults 65 and older

In the pooled placebo- and active-controlled glycemic trials, 744 of the Ozempic-treated patients (23.6%) were 65 or older. In SUSTAIN-6, the cardiovascular outcomes trial, 788 patients on Ozempic (48%) were 65 or older and 157 (9.6%) were 75 or older [1]. The label's geriatric use section says no overall differences in safety or efficacy were detected between these patients and younger patients, but that greater sensitivity of some older individuals cannot be ruled out [1].

In the pooled placebo-controlled glycemic trials the mean age was 56 and 3.4% of patients were 75 or older [1].

Ozempic is approved for three jobs in adults with type 2 diabetes: improving glycemic control alongside diet and exercise, reducing the risk of major adverse cardiovascular events in people with established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in people with chronic kidney disease [1].

Fitting the weekly injection around classes, appointments and outings

Ozempic is given once weekly, on the same day each week, at any time of day, with or without meals [1]. The label allows the weekday to change as long as the doses are more than 48 hours apart [1]. If a dose is missed, the label says to give it within 5 days of the missed dose; otherwise the missed dose is skipped [1].

Injections go under the skin in the abdomen, thigh or upper arm, using a different site each week when injecting in the same body region [1]. Two label points matter in a household: an Ozempic pen must never be shared between patients, even if the needle is changed, and the label tells prescribers to instruct patients to inform healthcare providers of any planned surgery or procedure, because pulmonary aspiration has been reported with GLP-1 receptor agonists during general anesthesia or deep sedation [1].

Nausea, vomiting and diarrhea: the numbers, and when they cluster

In the pooled placebo-controlled trials (262 patients on placebo, 260 on 0.5 mg, 261 on 1 mg, mean 32.9 weeks), nausea was reported by 6.1% on placebo, 15.8% on 0.5 mg and 20.3% on 1 mg; vomiting by 2.3%, 5% and 9.2%; diarrhea by 1.9%, 8.5% and 8.8%; and constipation by 1.5%, 5% and 3.1% [1]. Any gastrointestinal reaction was reported by 15.3%, 32.7% and 36.4% respectively, and treatment was stopped for GI reasons by 0.4%, 3.1% and 3.8% [1]. Severe GI reactions occurred in 0% on placebo, 0.4% on 0.5 mg and 0.8% on 1 mg [1].

The label states that the majority of reports of nausea, vomiting and diarrhea occurred during dose escalation [1]. In a separate 40-week trial of 959 patients comparing 2 mg with 1 mg, GI reactions occurred in 34% on 2 mg and 30.8% on 1 mg [1].

Ozempic is not recommended in patients with severe gastroparesis [1]. The labels do not state that semaglutide causes gastroparesis; postmarketing reports list ileus, intestinal obstruction and severe constipation including fecal impaction [1].

Hypoglycemia when insulin or a sulfonylurea is also in the mix

Ozempic raises the risk of hypoglycemia when it is used with an insulin secretagogue such as a sulfonylurea or with insulin, and the label says to consider reducing the dose of the sulfonylurea or insulin when Ozempic is started [1]. In the label's 30-week add-on-to-basal-insulin trial, documented symptomatic hypoglycemia at a 70 mg/dL threshold occurred in 15.2% on placebo, 16.7% on 0.5 mg and 29.8% on 1 mg. Severe hypoglycemia, defined as an episode requiring another person's assistance, occurred in 0%, 0% and 1.5% [1]. On monotherapy the same documented symptomatic threshold was met by 0%, 1.6% and 3.8% [1]. The label notes hypoglycemia was more frequent when Ozempic was combined with a sulfonylurea, and it says patients on these combinations should be informed of the risk and taught the signs and symptoms of hypoglycemia [1].

Fluid loss, kidneys and fall-prevention resources

Postmarketing reports of acute kidney injury, some requiring hemodialysis, have occurred with semaglutide, and the label says the majority of these events followed GI reactions that led to dehydration, such as nausea, vomiting or diarrhea [1]. The label advises monitoring renal function in patients with reactions that could cause volume depletion, especially during initiation and dose escalation [1]. No dose adjustment is recommended for renal impairment, and a pharmacokinetic study found no clinically relevant change in semaglutide exposure in people with renal impairment including kidney failure [1].

The CDC STEADI program provides a fall-risk screening algorithm and a Stay Independent checklist for older adults and caregivers [2].

Vision: reading, screens and activities that depend on it

In a 2-year trial in people with type 2 diabetes and high cardiovascular risk, diabetic retinopathy complications occurred in 3.0% on semaglutide and 1.8% on placebo; among those with retinopathy at baseline the rates were 8.2% and 5.2% [1]. The label says patients with a history of diabetic retinopathy should be monitored for progression, and that rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy [1].

Europe's medicines safety committee concluded in June 2025 that NAION, a form of sudden optic-nerve vision loss, is a very rare side effect of semaglutide, affecting up to 1 in 10,000 people, corresponding to roughly one additional case per 10,000 person-years and about a two-fold relative risk in large studies of adults with type 2 diabetes. It advised that semaglutide be stopped if NAION is confirmed [3]. The current US Ozempic injection label does not mention NAION [1].

How the dose goes up

The label's steps are 0.25 mg once weekly for 4 weeks, then 0.5 mg; 1 mg after at least 4 more weeks on 0.5 mg if more glycemic control is needed; then 2 mg after at least 4 weeks on 1 mg, with 2 mg the maximum weekly dose [1]. The 0.25 mg starting dose is not a maintenance dose [1]. For the kidney indication, the label moves to 1 mg after at least 4 weeks on 0.5 mg [1].

Other medicines in the cabinet

Ozempic delays gastric emptying and may affect how oral medicines are absorbed; its label advises caution when oral medicines are taken with it [1]. In clinical pharmacology trials, semaglutide did not affect the absorption of oral medicines to a clinically relevant degree [1]. The Rybelsus and Ozempic tablets label, a different product from the injection, reports that levothyroxine total exposure rose 33% when given with semaglutide tablets [4].

Weight at Ozempic doses

At Ozempic doses, SUSTAIN FORTE randomized 961 adults with type 2 diabetes on metformin to 2 mg or 1 mg weekly for 40 weeks: weight fell 6.9 kg on 2 mg and 6.0 kg on 1 mg, and HbA1c fell 2.2 percentage points on 2 mg and 1.9 points on 1 mg under the trial-product analysis [5].